Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 514
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 151–159 of 159 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04165330	Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors	active not recruiting	Phase 1 / Phase 2	56	Sarcoma Oncology Research Center, LLCOTHER	1	Feb 24, 2025	clinicaltrials
NCT03212404	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	active not recruiting	Phase 1	272	Checkpoint Therapeutics, Inc.INDUSTRY	9	Feb 3, 2025	clinicaltrials